Tepmitco tablets 250mg, with the ingredient Tepotinib hydrochloride hydrate, are produced by Merck Biopharma. This medication (YJ code: 4291065F1024, 250mg x 1 tablet) is a kinase inhibitor indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults with mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Tepmitco tablets 250mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →